Mural Oncology Plc (MURA) AI Stock Analysis

• Market Cap: $35.86M
• Dividend Yield: N/A
• Average Volume (3M): 452.05K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.38
• Revenue Growth: N/A
• EPS Growth: 17.06%
• Country: US
• Employees: 116
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -2.78
• Shares Outstanding: 17,324,360
• 10 Day Avg. Volume: 253,156
• 30 Day Avg. Volume: 452,048
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.87
• Enterprise Value/Revenue: -8.94
• Enterprise Value/Gross Profit: 8.40
• Enterprise Value/Ebitda: 0.21
• 1Y Price Target: $6.00
• Price Target Upside: 189.86% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: ―

Mural Oncology Plc's stock is weighed down by its financial challenges, including zero revenue and high cash burn, which significantly impact its overall score. Technical indicators suggest some positive momentum, but the stock faces resistance. Valuation remains unattractive due to unprofitability. However, upcoming clinical milestones and strategic focus on efficiency provide potential upside, reflected in the corporate events score.

Positive Factors

Mucosal Melanoma Trials

Topline data from cohort 2 of ARTISTRY-6 remains on-track for a potentially registrational readout evaluating nemvaleukin monotherapy in patients with mucosal melanoma.

Positive Interim Data Impact

Positive interim Phase 3 data should have a significant impact on investors' perception of MURA and lift the historical overhang from the IL-2 drug space.

Potential New Opportunities

Mural's next catalyst is Phase 2 mucosal melanoma data, potentially providing a new opportunity for success.

Negative Factors

Clinical Development Challenges

MURA announced its decision to discontinue clinical development of nemvaleukin.

Phase 3 Study Outcome

The interim analysis of the Phase 3 ARTISTRY-7 study failed to show a statistically significant overall survival benefit over investigator’s choice chemotherapy in platinum-resistant ovarian cancer (PROC).

Workforce Reduction

The company will undertake a reduction in its employee workforce of ~90%.

Mural Oncology Plc Business Overview & Revenue Model

Company Description

Mural Oncology Plc (MURA) is a biotechnology company focused on the development and commercialization of innovative cancer therapies. Operating within the pharmaceutical and healthcare sectors, Mural Oncology is dedicated to researching and delivering cutting-edge treatments that address unmet needs in oncology. The company's core products include targeted therapies and immuno-oncology treatments designed to improve patient outcomes and quality of life for those battling various forms of cancer.

How the Company Makes Money

Mural Oncology Plc generates revenue primarily through the sale of its proprietary cancer therapies and treatments. The company engages in licensing agreements and collaborations with pharmaceutical companies and research institutions to enhance its product pipeline and expand market reach. Additionally, Mural Oncology may receive milestone payments and royalties from partnerships, contributing to its revenue. The company also invests in clinical trials and regulatory approvals to ensure the successful commercialization of its therapies, which in turn drives sales and profitability.

Mural Oncology Plc Financial Statement Overview

Summary

Mural Oncology Plc faces challenges typical of early-stage biotech firms, with zero revenue and high R&D expenses leading to continuous losses. The company maintains a strong cash position and low debt, which are positives, but the lack of revenue generation and high cash burn rate present significant financial risks.

Income Statement

Mural Oncology Plc has consistently reported zero revenue over the past years, indicating a lack of commercialization of its products. The company has incurred significant losses, with a net loss of $128.5 million in 2024. This reflects the high R&D costs typical in the biotechnology industry without offsetting revenue.

Balance Sheet

The company has a relatively healthy equity position with a stockholders' equity of $140.5 million as of 2024. However, it has a low debt-to-equity ratio due to minimal debt, which is a positive sign of low leverage. The high cash reserves provide a cushion, but the continuous net losses are concerning for long-term sustainability.

Cash Flow

Mural Oncology Plc has negative operating cash flow and free cash flow, indicating cash burn without incoming revenue. Despite this, the company raised significant capital in previous years, ensuring liquidity in the short term. However, the lack of cash flow generation from operations remains a significant risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.49M	0.00	0.00	0.00	0.00
Gross Profit	-3.72M	-3.51M	-2.57M	-1.54M	-1.47M
EBITDA	-148.60M	-125.00M	-192.72M	-183.38M	-173.89M
Net Income	-147.15M	-128.51M	-207.45M	-200.03M	-175.43M
Balance Sheet
Total Assets	87.56M	169.39M	301.75M	33.75M	35.11M
Cash, Cash Equivalents and Short-Term Investments	77.09M	144.38M	270.85M	-19.39M	-25.31M
Total Debt	5.17M	8.02M	15.01M	19.39M	25.31M
Total Liabilities	28.77M	28.89M	37.93M	55.41M	52.99M
Stockholders Equity	58.78M	140.50M	263.82M	-21.66M	-17.88M
Cash Flow
Free Cash Flow	-130.06M	-128.64M	-197.70M	-174.10M	-161.05M
Operating Cash Flow	-130.01M	-128.54M	-194.25M	-168.59M	-156.67M
Investing Cash Flow	85.29M	-25.33M	-3.45M	-5.51M	-4.38M
Financing Cash Flow	224.00K	196.00K	468.81M	174.10M	161.05M

Mural Oncology Plc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MURA, the sentiment is Neutral. The current price of 2.07 is above the 20-day moving average (MA) of 1.93, below the 50-day MA of 2.19, and below the 200-day MA of 2.89, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 51.65 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MURA.

Mural Oncology Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EQ	56 Neutral	$113.65M	―	-146.92%	―	-61.16%	-139.15%
Sector *	55 Neutral	$6.28B	4.59	-14.06%	6.01%	10.84%	8.15%
MURA	43 Neutral	$35.86M	―	-111.75%	―	―	17.06%
LSTA	43 Neutral	$19.00M	―	-63.84%	―	―	12.95%
BCAB	35 Underperform	$31.50M	―	-813.88%	―	―	49.48%
ELEV	33 Underperform		―		―	―	47.73%
JUNS	―	$42.84M	―		―	―	―

Mural Oncology Plc Corporate Events

Mural Oncology Highlights 2024 Financial Results and Strategic Focus

On March 11, 2025, Mural Oncology announced its financial results for the fourth quarter and year-end 2024, highlighting a strategic focus on operational efficiency that extended their cash runway into Q1 2026. The company is preparing for significant clinical milestones in 2025, including interim data from the ARTISTRY-7 trial in ovarian cancer and top-line data from the ARTISTRY-6 trial in mucosal melanoma. These trials, involving their lead candidate nemvaleukin alfa, could impact Mural’s market positioning and offer potential value creation opportunities. Additionally, Mural expanded its pipeline with two new development candidates, MURA-8518 and MURA-7012, aimed at enhancing immune response and reducing toxicity.